Market Cap | 218.66M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -94.9M | Forward P/E | -2.02 | EPS next Y | -15.90% | 50D Avg Chg | -27.00% |
Sales | 2.07M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -13.00% |
Dividend | N/A | Price/Book | 1.00 | EPS next 5Y | - | 52W High Chg | -44.00% |
Recommedations | 2.80 | Quick Ratio | 14.66 | Shares Outstanding | 84.87M | 52W Low Chg | 60.00% |
Insider Own | 0.47% | ROA | -24.57% | Shares Float | 63.17M | Beta | -0.72 |
Inst Own | 79.10% | ROE | -49.34% | Shares Shorted/Prior | 4.86M/7.92M | Price | 3.18 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 49,669 | Target Price | 21.67 |
Oper. Margin | -4,798.45% | Earnings Date | May 9 | Volume | 24,743 | Change | -2.91% |
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.
TD Cowen | Hold | Apr 16, 24 |
RBC Capital | Sector Perform | Mar 21, 24 |
Wedbush | Neutral | Mar 21, 24 |
Raymond James | Market Perform | Mar 20, 24 |
B. Riley Securities | Neutral | Mar 20, 24 |
Truist Securities | Hold | Mar 20, 24 |
RBC Capital | Sector Perform | Mar 20, 24 |
JonesTrading | Hold | Mar 20, 24 |
Truist Securities | Hold | Mar 19, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
GANNON STEVEN | Director Director | Aug 11 | Buy | 2.03 | 44,400 | 90,132 | 56,400 | 08/11/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Apr 20 | Sell | 6.02 | 1,289 | 7,760 | 326,841 | 04/22/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Apr 11 | Sell | 6.96 | 32,849 | 228,629 | 328,130 | 04/13/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Apr 06 | Sell | 7.55 | 2,181 | 16,467 | 360,979 | 04/08/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Apr 01 | Sell | 7.74 | 3,800 | 29,412 | 363,160 | 04/05/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Mar 30 | Sell | 7.52 | 300 | 2,256 | 366,960 | 04/01/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Mar 22 | Sell | 7.5 | 4,800 | 36,000 | 377,560 | 03/24/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Mar 17 | Sell | 7.53 | 3,604 | 27,138 | 382,360 | 03/21/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Mar 14 | Sell | 7.02 | 1,500 | 10,530 | 385,964 | 03/16/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Mar 09 | Sell | 7.04 | 2,822 | 19,867 | 387,464 | 03/14/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Mar 04 | Sell | 7.08 | 14,504 | 102,688 | 390,286 | 03/08/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Feb 24 | Sell | 7.46 | 13,752 | 102,590 | 432,383 | 02/28/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Feb 18 | Sell | 7.83 | 38,297 | 299,866 | 446,135 | 02/23/22 |
Valliant John | Chief Executive Offi.. Chief Executive Officer | Feb 15 | Sell | 8.1 | 47,502 | 384,766 | 484,432 | 02/17/22 |